Based on prior knowledge regarding the use of a thrombospondin-targeting anticancer peptide in the same melanoma allograft model20, we further highlighted that lumican host expression strongly influences tumor response to ECM-targeted therapy. This evidence concerns the gene LUM and melanoma.